Alzheimer disease trials in Ukraine
4 trials · From ClinicalTrials.gov, checked 10 November 2026. Ask the study team whether a trial fits you.
- Phase 3Taking peopleA Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease
- Where
- Dnipro, Hlevakha, Kropyvnytskyi, Kyiv, Lutsk, Lviv, Oleksandrivka, Poltava, Skarzhyntsi, Smila, Ternopil, Vinnytsia
- Age
- 55 years to 90 years
- People
- 426 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT07011745 · EU 2025-520612-34-00 - Phase 3Taking peopleA Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
- Where
- Khmelnytskyi, Lviv, Smila, Ternopil, Uzhhorod, Vinnytsia
- Age
- 55 years to 90 years
- People
- 406 worldwide
- Run by
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
See details and how to joinNCT06585787 · EU 2024-516363-92-00 - Phase 3Taking peopleOpen-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)
- Where
- Khmelnytskyi, Lviv, Smila, Ternopil, Uzhhorod, Vinnytsia
- Age
- 55 years to 90 years
- People
- 1,000 worldwide
- Run by
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
See details and how to joinNCT05980949 · EU 2023-504151-27-00 - Phase 3Taking peopleA Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)
- Where
- Dnipro, Hlevakha, Kropyvnytskyi, Kyiv, Lviv, Oleksandrivka, Poltava, Skarzhyntsi, Smila, Ternopil, Vinnytsia
- Age
- 55 years to 90 years
- People
- 650 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT06937229 · EU 2024-519994-20-00